In the latest quarter, 4 analysts provided ratings for Integer Holdings (NYSE:ITGR), showcasing a mix of bullish and bearish perspectives.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
---|---|---|---|---|---|
Total Ratings | 2 | 2 | 0 | 0 | 0 |
Last 30D | 1 | 0 | 0 | 0 | 0 |
1M Ago | 0 | 1 | 0 | 0 | 0 |
2M Ago | 1 | 0 | 0 | 0 | 0 |
3M Ago | 0 | 1 | 0 | 0 | 0 |
The 12-month price targets, analyzed by analysts, offer insights with an average target of $147.25, a high estimate of $154.00, and a low estimate of $140.00. Highlighting a 1.17% decrease, the current average has fallen from the previous average price target of $149.00.
A comprehensive examination of how financial experts perceive Integer Holdings is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating |Current Price Target| Prior Price Target | |--------------------|--------------------|---------------|---------------|--------------------|--------------------| |Richard Newitter |Truist Securities |Lowers |Buy | $140.00|$163.00 | |Andrew Cooper |Raymond James |Announces |Outperform | $145.00|- | |Robert Wasserman |Benchmark |Raises |Buy | $150.00|$140.00 | |Brett Fishbin |Keybanc |Raises |Overweight | $154.00|$144.00 |
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Integer Holdings's market standing. Stay informed and make well-considered decisions with our Ratings Table.
Stay up to date on Integer Holdings analyst ratings.
Integer Holdings Corp is a manufacturer of medical device components used by original equipment manufacturers in the medical industry. The company also develops batteries used in nonmedical applications in the energy, military, and environmental markets. The firm organizes itself into one segment and derives its revenues from three product lines: Cardio & Vascular, Cardiac Rhythm Management & Neuromodulation and Other Markets. The company earns more than half of its revenue in the United States.
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Integer Holdings displayed positive results in 3M. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately 11.12%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Integer Holdings's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of 7.28%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Integer Holdings's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 2.02%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Integer Holdings's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of 1.05%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Integer Holdings's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.68.
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. Click here to stay ahead of the market.
This article was generated by Benzinga's automated content engine and reviewed by an editor.